SEC For	rm 4																	
FORM 4 UNITED STA					TES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549											OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See						Pursuant to Section 16(a) of the Securities Exchange Act of 1934										OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
1. Name and Address of Reporting Person* <u>Klencke Barbara</u>						eFFECTOR Therapeutics, Inc. [EFTR] (Check									-			
(Last)					3. Date of Earliest Transaction (Month/Day/Year) 02/19/2024									(give title	e title Other (specify below)			
C/O EFFECTOR THERAPEUTICS, INC. 142 NORTH CEDROS AVENUE, SUITE B					lf Amer	ndment,	Date	of Original F	iled (I	Month/D	Lin	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting						
(Street) SOLANA BEACH CA 92075				R	Rule 10b5-1(c) Transaction Indication													
(City)	(S		(Zip)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/D)					ar) if	A. Deemed xecution Date any Month/Day/Yea		a, 3. Transact Code (In	ion	4. Securities Acquired (A on Disposed Of (D) (Instr. 3,		ed (A) or	5. Amou Securitie Benefici Owned I	nt of es ally Following	Form (D) of	m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code \	/	Amount	(A) o (D)	r Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Trans Code 8)	action	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisabl Expiration Date (Month/Day/Year)				d f g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$11.32	02/19/2024		Α		2,000		(1)	02/	/18/2034	Common Stock	2,000	\$0.00	2,000)	D		

Explanation of Responses:

1. The shares subject to the option will vest in substantially equal monthly installments over 12 months, commencing on February 19, 2024, subject to the Reporting Person's continued service with the Issuer through each vesting date.

Remarks:

/s/ Michael Byrnes, Attorney-02/21/2024

in-Fact for Barbara Klencke

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.